Orchestra BioMed Holdings, Inc.
OBIO
$2.44
-$0.62-20.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.09% | -4.73% | 3.47% | -18.70% | -5.03% |
| Total Depreciation and Amortization | -1.19% | 10.53% | 2.70% | 0.00% | 2.78% |
| Total Amortization of Deferred Charges | 48.39% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.38% | 68.85% | -12.93% | 24.66% | 11.88% |
| Change in Net Operating Assets | 27.37% | -113.30% | -120.81% | 267.45% | -1,481.03% |
| Cash from Operations | -22.74% | 1.18% | -34.23% | 22.17% | -19.50% |
| Capital Expenditure | -5.66% | -55.88% | 36.45% | -1,237.50% | -366.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 530.57% | -587.20% | -94.07% | 79.43% | -82.29% |
| Cash from Investing | 446.36% | -773.79% | -94.66% | 77.85% | -82.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 78.43% | -99.66% | 8,692.40% | 850.00% | -88.24% |
| Repurchase of Common Stock | 29.64% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -102.12% | -7.24% | 8,692.40% | 850.00% | 100.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.02% | -276.74% | 386.38% | 105.38% | -163.02% |